164 related articles for article (PubMed ID: 9018234)
1. Antitumor effect of locally produced CD95 ligand.
Seino K; Kayagaki N; Okumura K; Yagita H
Nat Med; 1997 Feb; 3(2):165-70. PubMed ID: 9018234
[TBL] [Abstract][Full Text] [Related]
2. CD95L mediates tumor counterattack in vitro but induces neutrophil-independent tumor rejection in vivo.
Igney FH; Behrens CK; Krammer PH
Int J Cancer; 2005 Jan; 113(1):78-87. PubMed ID: 15386427
[TBL] [Abstract][Full Text] [Related]
3. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
[TBL] [Abstract][Full Text] [Related]
4. CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice.
Behrens CK; Igney FH; Arnold B; Möller P; Krammer PH
J Immunol; 2001 Mar; 166(5):3240-7. PubMed ID: 11207278
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil-dependent tumor rejection and priming of tumoricidal CD8+ T cell response induced by dendritic cells overexpressing CD95L.
Buonocore S; Haddou NO; Moore F; Florquin S; Paulart F; Heirman C; Thielemans K; Goldman M; Flamand V
J Leukoc Biol; 2008 Sep; 84(3):713-20. PubMed ID: 18567840
[TBL] [Abstract][Full Text] [Related]
6. Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo.
Ehl S; Hoffmann-Rohrer U; Nagata S; Hengartner H; Zinkernagel R
J Immunol; 1996 Apr; 156(7):2357-60. PubMed ID: 8786290
[TBL] [Abstract][Full Text] [Related]
7. CD95 ligand expression as a mechanism of immune escape in breast cancer.
Müschen M; Moers C; Warskulat U; Even J; Niederacher D; Beckmann MW
Immunology; 2000 Jan; 99(1):69-77. PubMed ID: 10651943
[TBL] [Abstract][Full Text] [Related]
8. CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants.
Eberle J; Fecker LF; Hossini AM; Wieder T; Daniel PT; Orfanos CE; Geilen CC
Oncogene; 2003 Dec; 22(57):9131-41. PubMed ID: 14668794
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL).
Drozdzik M; Qian C; Lasarte JJ; Bilbao R; Prieto J
Gene Ther; 1998 Dec; 5(12):1622-30. PubMed ID: 10023441
[TBL] [Abstract][Full Text] [Related]
10. Defining CD95 as a tumor suppressor gene.
Müschen M; Warskulat U; Beckmann MW
J Mol Med (Berl); 2000; 78(6):312-25. PubMed ID: 11001528
[TBL] [Abstract][Full Text] [Related]
11. T cell activation-induced and HIV tat-enhanced CD95(APO-1/Fas) ligand transcription involves NF-kappaB.
Li-Weber M; Laur O; Dern K; Krammer PH
Eur J Immunol; 2000 Feb; 30(2):661-70. PubMed ID: 10671224
[TBL] [Abstract][Full Text] [Related]
12. Deregulation of the CD95/CD95L system in lymphocytes from patients with primary acute HIV infection.
Cossarizza A; Stent G; Mussini C; Paganelli R; Borghi V; Nuzzo C; Pinti M; Pedrazzi J; Benatti F; Esposito R; Røsok B; Nagata S; Vella S; Franceschi C; De Rienzo B
AIDS; 2000 Mar; 14(4):345-55. PubMed ID: 10770536
[TBL] [Abstract][Full Text] [Related]
13. The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis.
Tolomeo M; Dusonchet L; Meli M; Grimaudo S; D'Alessandro N; Papoff G; Ruberti G; Rausa L
Cell Death Differ; 1998 Sep; 5(9):735-42. PubMed ID: 10200532
[TBL] [Abstract][Full Text] [Related]
14. The influence of CD95L expression on tumor rejection in mice.
Igney FH; Behrens CK; Krammer PH
Eur J Immunol; 2003 Oct; 33(10):2811-21. PubMed ID: 14515265
[TBL] [Abstract][Full Text] [Related]
15. p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis.
Pohl U; Wagenknecht B; Naumann U; Weller M
Cell Physiol Biochem; 1999; 9(1):29-37. PubMed ID: 10352342
[TBL] [Abstract][Full Text] [Related]
16. Fas/Apo-1 (CD95)-mediated apoptosis of neutrophils with Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation by neutrophilic polymorphonuclear leukocytes associated with antitumor immunity.
Shimizu M; Fontana A; Takeda Y; Yoshimoto T; Tsubura A; Matsuzawa A
Cell Immunol; 2001 Jan; 207(1):41-8. PubMed ID: 11161452
[TBL] [Abstract][Full Text] [Related]
17. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts.
Allison J; Georgiou HM; Strasser A; Vaux DL
Proc Natl Acad Sci U S A; 1997 Apr; 94(8):3943-7. PubMed ID: 9108084
[TBL] [Abstract][Full Text] [Related]
18. A regulatory element in the CD95 (APO-1/Fas) ligand promoter is essential for responsiveness to TCR-mediated activation.
Li-Weber M; Laur O; Hekele A; Coy J; Walczak H; Krammer PH
Eur J Immunol; 1998 Aug; 28(8):2373-83. PubMed ID: 9710215
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the proinflammatory effects of Fas ligand (CD95L).
Chen JJ; Sun Y; Nabel GJ
Science; 1998 Nov; 282(5394):1714-7. PubMed ID: 9831564
[TBL] [Abstract][Full Text] [Related]
20. Clonal deletion of major histocompatibility complex class I-restricted CD4+CD8+ thymocytes in vitro is independent of the CD95 (APO-1/Fas) ligand.
Müller KP; Mariani SM; Matiba B; Kyewski B; Krammer PH
Eur J Immunol; 1995 Oct; 25(10):2996-9. PubMed ID: 7589104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
